Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company focuses on innovative targeted and immune-mediated cancer therapies, with a leadership team experienced in oncology drug discovery and development. Supported by a strong investor syndicate, Tempest aims to bring meaningful benefits to patients with cancer.
Industries
Nr. of Employees
small (1-50)
Tempest Therapeutics
2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005
Patents
Products
Clinical‑stage oral PPARα antagonist (selective small molecule)
An orally administered selective antagonist targeting PPARα designed to inhibit tumor cell metabolic pathways (fatty acid oxidation) and to modulate suppressive immune cell populations; evaluated as monotherapy and in combination with immune checkpoint inhibitors in early‑phase clinical studies.
Clinical‑stage oral EP2/EP4 prostaglandin receptor dual antagonist
An orally available small molecule designed to block EP2 and EP4 prostaglandin receptors to reduce tumor-promoting signaling and suppressive immune populations; studied as monotherapy and in combination with checkpoint inhibitors in early‑phase clinical trials.
Orally delivered TREX‑1 inhibitor for STING pathway activation
A small molecule intended to inhibit the TREX‑1 exonuclease to increase tumor cytosolic DNA and selectively activate the cGAS/STING innate immune pathway in tumors, with the goal of inducing tumor‑specific immunity via systemic oral dosing.
Clinical‑stage oral PPARα antagonist (selective small molecule)
An orally administered selective antagonist targeting PPARα designed to inhibit tumor cell metabolic pathways (fatty acid oxidation) and to modulate suppressive immune cell populations; evaluated as monotherapy and in combination with immune checkpoint inhibitors in early‑phase clinical studies.
Clinical‑stage oral EP2/EP4 prostaglandin receptor dual antagonist
An orally available small molecule designed to block EP2 and EP4 prostaglandin receptors to reduce tumor-promoting signaling and suppressive immune populations; studied as monotherapy and in combination with checkpoint inhibitors in early‑phase clinical trials.
Orally delivered TREX‑1 inhibitor for STING pathway activation
A small molecule intended to inhibit the TREX‑1 exonuclease to increase tumor cytosolic DNA and selectively activate the cGAS/STING innate immune pathway in tumors, with the goal of inducing tumor‑specific immunity via systemic oral dosing.
Services
Design and execution of multicenter oncology clinical studies, including partnership arrangements where an external partner manages study operations.
Preclinical program support including immune cell assays using PBMCs, animal tumor models, mechanism-based biomarker identification, and IND‑enabling studies.
Development and execution of regulatory strategies for global filings (INDs, CTAs, NDAs) and submission support including orphan and expedited program planning.
Design and execution of multicenter oncology clinical studies, including partnership arrangements where an external partner manages study operations.
Preclinical program support including immune cell assays using PBMCs, animal tumor models, mechanism-based biomarker identification, and IND‑enabling studies.
Development and execution of regulatory strategies for global filings (INDs, CTAs, NDAs) and submission support including orphan and expedited program planning.
Expertise Areas
- Clinical trial management (early and late stage)
- Regulatory strategy and global submissions
- Small‑molecule discovery and translational oncology
- CMC and medicinal chemistry
Key Technologies
- Orally delivered small‑molecule therapeutics
- PPARα pathway modulation
- EP2/EP4 prostaglandin receptor antagonism
- TREX‑1 inhibition and cGAS/STING pathway modulation
News & Updates
Management will present at the Jefferies Healthcare Conference on June 3, 2021, at 3:00 p.m. ET. The presentation will be available on the company's website.
Tempest announced FDA clearance for IND of TPST-1495, a dual antagonist of EP2 and EP4 prostaglandin receptors, enabling initiation of Phase 1a/1b clinical trial. The company also received new investments from Lyfe Capital and Rock Springs Capital.
The company announced the completion of a $70 million Series B financing led by Versant Ventures and others, supporting the advancement of its oncology programs.
Management will present at the Jefferies Healthcare Conference on June 3, 2021, at 3:00 p.m. ET. The presentation will be available on the company's website.
Tempest announced FDA clearance for IND of TPST-1495, a dual antagonist of EP2 and EP4 prostaglandin receptors, enabling initiation of Phase 1a/1b clinical trial. The company also received new investments from Lyfe Capital and Rock Springs Capital.
The company announced the completion of a $70 million Series B financing led by Versant Ventures and others, supporting the advancement of its oncology programs.